Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001)

NCT: NCT05089786 · WITHDRAWN

NCT IDNCT05089786
StatusWITHDRAWN
Start Date2022-12-31
Completion2025-02-28

Brief Summary

Evaluate the safety and effectiveness of Echo-Focusing using Exablate Neuro as a tool for treating patients with treatment-refractory neurologic and psychiatric disorders.

Frequently Asked Questions

What is Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001)?

Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) is a clinical trial registered under NCT05089786. Current status: WITHDRAWN.

What is the status of NCT05089786?

The current status of NCT05089786 (Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001)) is: WITHDRAWN.

When did Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) start?

Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) started on 2022-12-31.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑